Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. HROW
stocks logo

HROW

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
88.90M
+33.02%
0.386
+60.94%
68.68M
+43.59%
-0.038
-92.33%
89.91M
+41.05%
0.288
+121.79%
Estimates Revision
The market is revising Downward the revenue expectations for Harrow, Inc. (HROW) for FY2025, with the revenue forecasts being adjusted by -3.68% over the past three months. During the same period, the stock price has changed by 26.44%.
Revenue Estimates for FY2025
Revise Downward
down Image
-3.68%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-80.33%
In Past 3 Month
Stock Price
Go Up
up Image
+26.44%
In Past 3 Month
Wall Street analysts forecast HROW stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HROW is 72.67 USD with a low forecast of 63.00 USD and a high forecast of 94.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast HROW stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HROW is 72.67 USD with a low forecast of 63.00 USD and a high forecast of 94.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 46.770
sliders
Low
63.00
Averages
72.67
High
94.00
Current: 46.770
sliders
Low
63.00
Averages
72.67
High
94.00
Ladenburg
Jeffrey Cohen
Buy
maintain
$64 -> $66
2025-11-12
Reason
Ladenburg
Jeffrey Cohen
Price Target
$64 -> $66
2025-11-12
maintain
Buy
Reason
Ladenburg analyst Jeffrey Cohen raised the firm's price target on Harrow to $66 from $64 and keeps a Buy rating on the shares. The firm updated the company's model post the Q3 report.
H.C. Wainwright
Buy
maintain
$64 -> $69
2025-11-12
Reason
H.C. Wainwright
Price Target
$64 -> $69
2025-11-12
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Harrow to $69 from $64 and keeps a Buy rating on the shares. The company reported a "robust" Q3 and its growth momentum for Vevye and Iheezo should continue in 2026, the analyst tells investors in a research note. The firm also believes Harrow's new product launches in 2026 should further drive sales growth.
Cantor Fitzgerald
NULL -> Overweight
maintain
$76 -> $94
2025-11-11
Reason
Cantor Fitzgerald
Price Target
$76 -> $94
2025-11-11
maintain
NULL -> Overweight
Reason
Cantor Fitzgerald raised the firm's price target on Harrow to $94 from $76 and keeps an Overweight rating on the shares.
Cantor Fitzgerald
Cantor Fitzgerald
Overweight
maintain
$76 -> $94
2025-11-11
Reason
Cantor Fitzgerald
Cantor Fitzgerald
Price Target
$76 -> $94
2025-11-11
maintain
Overweight
Reason
As previously reported, Cantor Fitzgerald raised the firm's price target on Harrow to $94 from $76 and keeps an Overweight rating on the shares following quarterly results. The firm now models $29M Vevye revenues in Q4, which would mean FY25 Vevye revenue would fall short of over $100M target/guidance by $8M -- not a huge deal, Cantor says, but increases pressure on 2026 where new insurance coverage and continued market share growth need to be matched by proportional revenue growth.
B. Riley
Buy
maintain
$70 -> $74
2025-10-01
Reason
B. Riley
Price Target
$70 -> $74
2025-10-01
maintain
Buy
Reason
B. Riley raised the firm's price target on Harrow to $74 from $70 and keeps a Buy rating on the shares following the analyst day. The firm says the company's pipeline portfolio and commercial roadmap up its confidence in a bullish long-term revenue and margin expansion thesis for Harrow.
Lake Street
Thomas Flaten
Buy
maintain
$42 -> $70
2025-09-29
Reason
Lake Street
Thomas Flaten
Price Target
$42 -> $70
2025-09-29
maintain
Buy
Reason
Lake Street analyst Thomas Flaten raised the firm's price target on Harrow to $70 from $42 and keeps a Buy rating on the shares. The company's investor day on Friday reinforced the firm's confidence in the company's ability to scale its business to $250M-plus in quarterly revenue by Q4 of 2027, the analyst tells investors. "It is hard to bet against success and Harrow has had plenty of it," adds the firm, which would remain buyers of the Harrow shares.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Harrow Inc (HROW.O) is 44.28, compared to its 5-year average forward P/E of 74.35. For a more detailed relative valuation and DCF analysis to assess Harrow Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
74.35
Current PE
44.28
Overvalued PE
343.48
Undervalued PE
-194.77

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
14.78
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
19.46
Undervalued EV/EBITDA
10.10

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.34
Current PS
0.00
Overvalued PS
4.54
Undervalued PS
2.15
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 135.73% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 135.73% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

HROW News & Events

Events Timeline

(ET)
2025-11-18
07:09:04
Harrow Completes Acquisition of Melt Pharmaceuticals
select
2025-11-10 (ET)
2025-11-10
16:45:35
Harrow announces Q3 core EPS of 33 cents, surpassing consensus estimate of 29 cents.
select
2025-09-26 (ET)
2025-09-26
11:56:59
Harrow Aims for Over $250M in Quarterly Revenue by the Fourth Quarter of 2027
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
11-24Newsfilter
Harrow to Participate in Two Investor Conferences Focused on Ophthalmic Management
  • Investor Conference Participation: Harrow will participate in two investor conferences on December 1 and 2, 2025, namely the BTIG 5th Annual Ophthalmology Day (virtual) and the Piper Sandler 37th Annual Healthcare Conference. These events will provide the company with opportunities to showcase its ophthalmic disease management solutions and attract potential investor interest.
  • Format and Timing: The BTIG conference is scheduled for December 1 at 8:30 AM EST, while the Piper Sandler conference will take place on December 2 at 3:00 PM EST. The Piper Sandler event will be webcast live, allowing investors to engage in real-time, with a replay available for approximately 90 days post-event.
  • Company Overview: Harrow is a leading provider of ophthalmic disease management solutions in North America, focusing on conditions such as dry eye disease, age-related macular degeneration, cataracts, and more. The company is committed to delivering safe, effective, and affordable medications that enhance patient compliance and improve clinical outcomes.
  • Strategic Implications: By participating in these conferences, Harrow aims to enhance its market visibility and strengthen connections with investors. This initiative will help the company solidify its position in the competitive healthcare market and drive future growth.
[object Object]
Preview
6.0
11-12Benzinga
HC Wainwright & Co. Reaffirms Buy Rating on Harrow, Increases Price Target to $69

  • Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts to stay updated on market movements.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.

  • Market Winning Tools: The platform is designed to help traders win in the markets every day with accurate stock market intelligence.

[object Object]
Preview
7.0
11-11SeekingAlpha
Harrow Revises 2025 Revenue Forecast to $270M–$280M, Fueled by VEVYE and IHEEZO's Significant Coverage Success

  • Management Insights: CEO Mark Baum highlighted Harrow's position as a leading provider of ophthalmic solutions, with significant growth expected from upcoming product launches and recent agreements for VEVYE, which will gain preferred status with major payers starting January 2026.

  • Financial Performance: Harrow reported a total revenue of $71.6 million for Q3 2025, a 45% increase year-over-year, with adjusted EBITDA of $22.7 million and GAAP net income of $1 million, while updating full-year revenue guidance to $270 million to $280 million.

  • Commercial Growth: The company saw a 36% increase in prescribing physicians for VEVYE, with both VEVYE and IHEEZO achieving strong quarter-over-quarter revenue growth, indicating robust market adoption and execution of commercial strategies.

  • Risks and Future Outlook: Management acknowledged an ongoing licensing dispute for ImprimisRx and an inventory shortage impacting Q4 revenue, but remains confident in the commercial strategy and future growth prospects as new payer coverage and expanded infrastructure are expected to drive market share gains.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Harrow Inc (HROW) stock price today?

The current price of HROW is 46.77 USD — it has increased 5.05 % in the last trading day.

arrow icon

What is Harrow Inc (HROW)'s business?

Harrow, Inc. is a provider of ophthalmic disease management solutions. It offers a portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. Its product candidates include MELT-210, MELT-300 and MELT-400. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.

arrow icon

What is the price predicton of HROW Stock?

Wall Street analysts forecast HROW stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HROW is 72.67 USD with a low forecast of 63.00 USD and a high forecast of 94.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Harrow Inc (HROW)'s revenue for the last quarter?

Harrow Inc revenue for the last quarter amounts to 71.64M USD, increased 45.44 % YoY.

arrow icon

What is Harrow Inc (HROW)'s earnings per share (EPS) for the last quarter?

Harrow Inc. EPS for the last quarter amounts to 0.03 USD, decreased -125.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Harrow Inc (HROW)'s fundamentals?

The market is revising Downward the revenue expectations for Harrow, Inc. (HROW) for FY2025, with the revenue forecasts being adjusted by -3.68% over the past three months. During the same period, the stock price has changed by 26.44%.
arrow icon

How many employees does Harrow Inc (HROW). have?

Harrow Inc (HROW) has 382 emplpoyees as of December 05 2025.

arrow icon

What is Harrow Inc (HROW) market cap?

Today HROW has the market capitalization of 1.73B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free